A Quantitative and Narrative Evaluation of Goodman and Gilman’s Pharmacological Basis of Therapeutics

Abstract

Goodman and Gilman's <i>The Pharmacological Basis of Therapeutics</i> (_GGPBT) has been a cornerstone in the education of pharmacists, physicians, and pharmacologists for decades. The objectives of this study were to describe and evaluate the 13^th edition of _GGPBT on bases including: (1) author characteristics; (2) recency of citations; (3) conflict of interest (CoI) disclosure; (4) expert evaluation of chapters. Contributors' (N = 115) sex, professional degrees, and presence of undisclosed potential CoI-as reported by the Center for Medicare and Medicaid's Open Payments (2013-2017)-were examined. The year of publication of citations was extracted relative to Katzung's <i>Basic and Clinical Pharmacology</i> (_KatBCP), and DiPiro's <i>Pharmacotherapy: A Pathophysiologic Approach</i> (_DiPPAPA). Content experts provided thorough chapter reviews. The percent of _GGPBT contributors that were female (20.9%) was equivalent to those in _KatBCP (17.0%). Citations in _GGPBT (11.5 ± 0.2 years) were significantly older than those in _KatBCP (10.4 ± 0.2) and _DiPPAPA (9.1 ± 0.1, <i>p</i> < 0.0001). Contributors to _GGPBT received USD 3 million in undisclosed remuneration (Maximum author = USD 743,718). In contrast, _DiPPAPA made CoI information available. Reviewers noted several strengths but also some areas for improvement. _GGPBT will continue to be an important component of the biomedical curriculum. Areas of improvement include a more diverse authorship, improved conflict of interest transparency, and a greater inclusion of more recent citations.